Relationship with immunhistochemical staining extent of CD47 and histopathologic features of bladder tumor

Abstract

IntroductionIt has been shown that CD47 is an important diagnostic and prognostic marker in many cancer types. However, the relationship between CD47 and bladder tumor stage has not been shown in previous studies. To the best of our knowledge, this is the first study investigating the association of CD47 with stages of bladder cancer.Material and methodsSurgical specimens of 175 patients were included in the study. The CD47 staining assessment was performed in the following categories; none, focal, moderate and diffuse. The statistics of the study were tested using t-test and analysis of variance.ResultsWe demonstrated much less CD47 staining extent in Ta tumor pathology compared to T1 and T1+T2+T3+T4 tumor pathology (p = 0.034 and p = 0.016, respectively). We also showed that the average value of CD47 staining extent with CIS+ was significantly higher compared to CIS– among NMIBC (p = 0.0248). However, no significant differences in CD47 staining pattern were observed in the following study groups: high vs. low-grade tumors in non-muscle invasive bladder cancer (NMIBC); MIBC (T2–T4) vs. NMIBC; lymph node involvement (N1–N3) vs. non-lymph node involvement (N0) in MIBC (T2–T4).ConclusionsOur study demonstrated that CD47 might have a critical role in the progression of Ta to T1 stage. Furthermore, we showed that CD47 is highly expressed in CIS+ NMIBC compared to CIS- NMIBC. Thus, differentiating stages with the help of this new potential marker may help clinicians treat bladder tumors better. Future studies to determine the role of CD47 on pathophysiology, diagnosis and prognosis of bladder tumor are warranted.

Evaluation of CD47 Expression in Solid Pancreatic Tumors Diagnosed with Endosonography Guided Fine Needle Aspiration Biopsy

“…Yuan et al (9) in patients with hormone receptor negative breast cancer and Lascorz et al (17) colorectal carcinomas showed that overexpression of CD47. In a study conducted by Olcucuoglu et al (7) high CD47 expression was reported to contribute to the evaluation of bladder tumors at various stages. These studies also showed that increased CD47 expression was a poor prognostic factor (7,9,17).…”

“…In a study conducted by Olcucuoglu et al (7) high CD47 expression was reported to contribute to the evaluation of bladder tumors at various stages. These studies also showed that increased CD47 expression was a poor prognostic factor (7,9,17). Moreover, studies have shown that this increased expression promotes the escape of cancer cells from phagocytosis (8,18).…”

“…By interacting with its ligands such as signal regulatory protein α and thrombospondin-1, it modulates cellular phagocytosis by macrophages, transmigration of neutrophils and activation of dendritic cells, T-cells and B-cells (4). CD47 expression was determined to be high in most solid organ malignancies (5,6,7,8,9,10). Since CD47 secretion in the cancer cell membrane would inhibit the phagocytic activity of immune cells; it is associated with a poor prognosis in many solid organ malignancies (8,11,12,13).…”

<p>Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies</p>

“…CD47 participates in tumor immune escape by combining with SIRPα in other cancers, such as glioblastoma, 42 leiomyosarcoma, 43 osteosarcoma, 44 malignant mesothelioma, 24,45 non-Hodgkin's lymphoma, 46 cervical cancer, ovarian cancer, renal cell carcinoma, [47][48][49] and bladder tumor. 50 Given that CD47 is widely expressed in various cancer types, it represents a potential and widely applicable target for immunotherapy. Using the mechanism of CD47-SIRPα interaction has achieved some success in anti-tumor research.…”

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma

“…Recently, much interest was attracted to the role of CD47 as a regulator of innate immune surveillance when bound to a membrane protein called SIRPα (SHPS-1/BIT/CD172a) on macrophages and other myeloid cells [ 7 ]. Phagocytosis is downregulated when SIRPα on a phagocyte binds with CD47 of the target cell [ 8 ]. Blocking CD47 makes it unable to restrain SIRPα, triggering phagocytosis [ 8 ] and creating an attractive therapeutic target.…”